

6 Literaturverzeichnis

- Abosch A, Kapur S, Lang AE, Hussey D, Sime E, Miyasaki J, Houle S, Lozano AM (2003) Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. *Neurosurgery* 53: 1095-1102.
- Aitken A (1996) 14-3-3 and its possible role in co-ordinating multiple signalling pathways. *Trends Cell Biol* 6: 341-347.
- Albin RL, Young AB, Penney JB (1989) The functional anatomy of basal ganglia disorders. *Trends Neurosci* 12: 366-375.
- Alexander GE, Crutcher MD (1990) Functional architecture of basal ganglia circuits: neural substrates of parallel processing. *Trends Neurosci* 13: 266-271.
- Arbuthnott GW, Fairbrother IS, Butcher SP (1990) Dopamine release and metabolism in the rat striatum: an analysis by 'in vivo' brain microdialysis. *Pharmacol Ther* 48: 281-293.
- Asanuma K, Tang C, Ma Y, Dhawan V, Mattis P, Edwards C, Kaplitt MG, Feigin A, Eidelberg D (2006) Network modulation in the treatment of Parkinson's disease. *Brain* 129: 2667-2678.
- Bacci JJ, Absi eH, Manrique C, Baunez C, Salin P, Kerkerian-Le Goff L (2004) Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. *Eur J Neurosci* 20: 3331-3341.
- Bejjani BP, Gervais D, Arnulf I, Papadopoulos S, Demeret S, Bonnet AM, Cornu P, Damier P, Agid Y (2000) Axial parkinsonian symptoms can be improved: the role of levodopa and bilateral subthalamic stimulation. *J Neurol Neurosurg Psychiatry* 68: 595-600.
- Benazzouz A, Gao D, Ni Z, Benabid AL (2000a) High frequency stimulation of the STN influences the activity of dopamine neurons in the rat. *Neuroreport* 11: 1593-1596.
- Benazzouz A, Gao DM, Ni ZG, Piallat B, Bouali-Benazzouz R, Benabid AL (2000b) Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. *Neuroscience* 99: 289-295.
- Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. *Eur J Neurosci* 5: 382-389.
- Benazzouz A, Piallat B, Pollak P, Benabid AL (1995) Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. *Neurosci Lett* 189: 77-80.
- Bennett DA, Beckett LA, Murray AM, Shannon KM, Goetz CG, Pilgrim DM, Evans DA (1996) Prevalence of parkinsonian signs and associated mortality in a community population of older people. *N Engl J Med* 334: 71-76.
- Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. *Science* 249: 1436-1438.
- Beurrier C, Bioulac B, Audin J, Hammond C (2001) High-frequency stimulation produces a transient blockade of voltage-gated currents in subthalamic neurons. *J Neurophysiol* 85: 1351-1356.
- Bevilaqua LR, Graham ME, Dunkley PR, Nagy-Felsobuki EI, Dickson PW (2001) Phosphorylation of Ser(19) alters the conformation of tyrosine hydroxylase to increase the rate of phosphorylation of Ser(40). *J Biol Chem* 276: 40411-40416.
- Bezard E, Brotchie JM, Gross CE (2001) Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. *Nat Rev Neurosci* 2: 577-588.

Birkmayer W, Hornykiewicz O (1961) [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]. Wien Klin Wochenschr 73: 787-788.

Birkmayer W, Hornykiewicz O (1962) [The L-dihydroxyphenylalanine (L-DOPA) effect in Parkinson's syndrome in man: On the pathogenesis and treatment of Parkinson akinesis.]. Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr 203: 560-574.

Bolam JP, Hanley JJ, Booth PA, Bevan MD (2000) Synaptic organisation of the basal ganglia. J Anat 196 (Pt 4): 527-542.

Boulet S, Lacombe E, Carcenac C, Feuerstein C, Sgambato-Faure V, Poupart A, Savasta M (2006) Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J Neurosci 26: 10768-10776.

Bowyer JF, Frame LT, Clausing P, Nagamoto-Combs K, Osterhout CA, Sterling CR, Tank AW (1998) Long-term effects of amphetamine neurotoxicity on tyrosine hydroxylase mRNA and protein in aged rats. J Pharmacol Exp Ther 286: 1074-1085.

Braak H, Braak E (2000) Pathoanatomy of Parkinson's disease. J Neurol 247 Suppl 2: II3-10.

Bracco F, Battaglia A, Chouza C, Dupont E, Gershnik O, Marti Masso JF, Montastruc JL (2004) The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs 18: 733-746.

Breier A, Su TP, Saunders R, Carson RE, Kolachana BS, de Bartolomeis A, Weinberger DR, Weisenfeld N, Malhotra AK, Eckelman WC, Pickar D (1997) Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc Natl Acad Sci U S A 94: 2569-2574.

Bruet N, Windels F, Bertrand A, Feuerstein C, Poupart A, Savasta M (2001) High frequency stimulation of the subthalamic nucleus increases the extracellular contents of striatal dopamine in normal and partially dopaminergic denervated rats. J Neuropathol Exp Neurol 60: 15-24.

Burchiel KJ, Anderson VC, Favre J, Hammerstad JP (1999) Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study. Neurosurgery 45: 1375-1382.

Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1988) Amphetamine-induced dopamine release in the rat striatum: an in vivo microdialysis study. J Neurochem 50: 346-355.

Butcher SP, Fairbrother IS, Kelly JS, Arbuthnott GW (1990) Effects of selective monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat striatum. J Neurochem 55: 981-988.

Callaway CW, Kuczynski R, Segal DS (1989) Reserpine enhances amphetamine stereotypies without increasing amphetamine-induced changes in striatal dialysate dopamine. Brain Res 505: 83-90.

Ceballos-Baumann AO, Boecker H, Bartenstein P, von F, I, Riescher H, Conrad B, Moringlane JR, Alesch F (1999) A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol 56: 997-1003.

Cenci MA, Kalen P, Mandel RJ, Bjorklund A (1992) Regional differences in the regulation of dopamine and noradrenaline release in medial frontal cortex, nucleus accumbens and caudate-putamen: a microdialysis study in the rat. Brain Res 581: 217-228.

Charles PD, Padaliya BB, Newman WJ, Gill CE, Covington CD, Fang JY, So SA, Tramontana MG, Konrad PE, Davis TL (2004) Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkinsonism Relat Disord 10: 475-479.

Colzi A, Turner K, Lees AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 64: 573-576.

Cooper I.S., Bravo G.J., Riklan M., Davidson N.W., Gorek E.A. (1958) Chemopallidectomy and chemothalamectomy for parkinsonism. *Geriatrics* 13: 127-147.

Cotzias GC, Van Woert MH, Schiffer LM (1967) Aromatic amino acids and modification of parkinsonism. *N Engl J Med* 276: 374-379.

Dahlstroem A, Fuxe K, Hillarp N (1965) Site Of Action Of Reserpine. *Acta Pharmacol Toxicol (Copenh)* 22: 277-292.

Daubner SC, Lauriano C, Haycock JW, Fitzpatrick PF (1992) Site-directed mutagenesis of serine 40 of rat tyrosine hydroxylase. Effects of dopamine and cAMP-dependent phosphorylation on enzyme. *J Biol Chem* 267: 12639-12646.

de Rijk MC, Tzourio C, Breteler MM, Dartigues JF, Amaducci L, Lopez-Pousa S, Manubens-Bertran JM, Alperovitch A, Rocca WA (1997) Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 62: 10-15.

Deep-Brain Stimulation for Parkinson's Disease Study Group (2001) Deep-brain stimulation of the subthalamic nucleus or the pars interna of the globus pallidus in Parkinson's disease. *N Engl J Med* 345: 956-963.

DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. *Trends Neurosci* 13: 281-285.

Deuschl G, Schade-Brittinger C, Krack P, Volkmann J, Schafer H, Botzel K, Daniels C, Deuschlander A, Dillmann U, Eisner W, Gruber D, Hamel W, Herzog J, Hilker R, Klebe S, Kloss M, Koy J, Krause M, Kupsch A, Lorenz D, Lorenzl S, Mehdorn HM, Moringlane JR, Oertel W, Pinsker MO, Reichmann H, Reuss A, Schneider GH, Schnitzler A, Steude U, Sturm V, Timmermann L, Tronnier V, Trottenberg T, Wojtecki L, Wolf E, Poewe W, Voges J (2006) A randomized trial of deep-brain stimulation for Parkinson's disease. *N Engl J Med* 355: 896-908.

Di Chiara G, Carboni E, Morelli M, Cozzolino A, Tanda GL, Pinna A, Russi G, Consolo S (1993) Stimulation of dopamine transmission in the dorsal caudate nucleus by pargyline as demonstrated by dopamine and acetylcholine microdialysis and Fos immunohistochemistry. *Neuroscience* 55: 451-456.

Diana M, Garcia-Munoz M, Richards J, Freed CR (1989) Electrophysiological analysis of dopamine cells from the substantia nigra pars compacta of circling rats. *Exp Brain Res* 74: 625-630.

Dostrovsky JO, Lozano AM (2002) Mechanisms of deep brain stimulation. *Mov Disord* 17 Suppl 3: S63-S68.

Elsworth JD, Roth RH (1997) Dopamine synthesis, uptake, metabolism, and receptors: relevance to gene therapy of Parkinson's disease. *Exp Neurol* 144: 4-9.

Elverfors A, Pileblad E, Lagerkvist S, Bergquist F, Jonason J, Nissbrandt H (1997) 3-Methoxytyramine formation following monoamine oxidase inhibition is a poor index of dendritic dopamine release in the substantia nigra. *J Neurochem* 69: 1684-1692.

Evers S, Obladen M (1994) [Epidemiology and therapy of Parkinson disease in inpatient nursing homes]. *Z Gerontol* 27: 270-275.

Ewing AG, Wightman RM (1984) Monitoring the stimulated release of dopamine with in vivo voltammetry. II: Clearance of released dopamine from extracellular fluid. *J Neurochem* 43: 570-577.

Filali M, Hutchison WD, Palter VN, Lozano AM, Dostrovsky JO (2004) Stimulation-induced inhibition of neuronal firing in human subthalamic nucleus. *Exp Brain Res* 156: 274-281.

Fisher RS, Levine MS, Sibley DR, Ariano MA (1994) D2 dopamine receptor protein location: Golgi impregnation-gold toning and ultrastructural analysis of the rat neostriatum. *J Neurosci Res* 38: 551-564.

Fraix V, Houeto JL, Lagrange C, Le Pen C, Krystkowiak P, Guehl D, Arduoin C, Welter ML, Maurel F, Defebvre L, Rougier A, Benabid AL, Mesnage V, Ligier M, Blond S, Burbaud P, Bioulac B, Destee A, Cornu P, Pollak P (2006) Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 77: 443-449.

Funakoshi H, Okuno S, Fujisawa H (1991) Different effects on activity caused by phosphorylation of tyrosine hydroxylase at serine 40 by three multifunctional protein kinases. *J Biol Chem* 266: 15614-15620.

Galloway MP, Wolf ME, Roth RH (1986) Regulation of dopamine synthesis in the medial prefrontal cortex is mediated by release modulating autoreceptors: studies in vivo. *J Pharmacol Exp Ther* 236: 689-698.

Garcia L, Audin J, D'Alessandro G, Bioulac B, Hammond C (2003) Dual effect of high-frequency stimulation on subthalamic neuron activity. *J Neurosci* 23: 8743-8751.

Gerhardt GA, Maloney RE, Jr. (1999) Microdialysis studies of basal levels and stimulus-evoked overflow of dopamine and metabolites in the striatum of young and aged Fischer 344 rats. *Brain Res* 816: 68-77.

Gingrich JA, Caron MG (1993) Recent advances in the molecular biology of dopamine receptors. *Annu Rev Neurosci* 16: 299-321.

Griffith LC, Schulman H (1988) The multifunctional Ca²⁺/calmodulin-dependent protein kinase mediates Ca²⁺-dependent phosphorylation of tyrosine hydroxylase. *J Biol Chem* 263: 9542-9549.

Grima B, Lamouroux A, Boni C, Julien JF, Javoy-Agid F, Mallet J (1987) A single human gene encoding multiple tyrosine hydroxylases with different predicted functional characteristics. *Nature* 326: 707-711.

Groenewegen HJ, Berendse HW (1990) Connections of the subthalamic nucleus with ventral striatopallidal parts of the basal ganglia in the rat. *J Comp Neurol* 294: 607-622.

Guldberg HC, Broch OJ, Jr. (1971) On the mode of action of reserpine on dopamine metabolism in the rat striatum. *Eur J Pharmacol* 13: 155-167.

Guldberg HC, Marsden CA (1975) Catechol-O-methyl transferase: pharmacological aspects and physiological role. *Pharmacol Rev* 27: 135-206.

Guldenpfennig WM, Poole KH, Sommerville KW, Boroojerdi B (2005) Safety, tolerability, and efficacy of continuous transdermal dopaminergic stimulation with rotigotine patch in early-stage idiopathic Parkinson disease. *Clin Neuropharmacol* 28: 106-110.

Hammond C, Deniau JM, Rizk A, Feger J (1978) Electrophysiological demonstration of an excitatory subthalamic pathway in the rat. *Brain Res* 151: 235-244.

Hariz MI (2002) Complications of deep brain stimulation surgery. *Mov Disord* 17 Suppl 3: S162-S166.

Hashimoto T, Elder CM, Okun MS, Patrick SK, Vitek JL (2003) Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. *J Neurosci* 23: 1916-1923.

Haslinger B, Kalteis K, Boecker H, Alesch F, Ceballos-Baumann AO (2005) Frequency-correlated decreases of motor cortex activity associated with subthalamic nucleus stimulation in Parkinson's disease. *Neuroimage* 28: 598-606.

Haycock JW (1990) Phosphorylation of tyrosine hydroxylase in situ at serine 8, 19, 31, and 40. *J Biol Chem* 265: 11682-11691.

Haycock JW, Ahn NG, Cobb MH, Krebs EG (1992) ERK1 and ERK2, two microtubule-associated protein 2 kinases, mediate the phosphorylation of tyrosine hydroxylase at serine-31 in situ. *Proc Natl Acad Sci U S A* 89: 2365-2369.

Haycock JW, Haycock DA (1991) Tyrosine hydroxylase in rat brain dopaminergic nerve terminals. Multiple-site phosphorylation in vivo and in synaptosomes. *J Biol Chem* 266: 5650-5657.

Henning J, Koczan D, Glass A, Karopka T, Pahnke J, Rolfs A, Benecke R, Gimsa U (2007) Deep brain stimulation in a rat model modulates TH, CaMKII α and Homer1 gene expression. *Eur J Neurosci* 25: 239-250.

Herzog J, Volkmann J, Krack P, Kopper F, Potter M, Lorenz D, Steinbach M, Klebe S, Hamel W, Schrader B, Weinert D, Muller D, Mehdorn HM, Deuschl G (2003) Two-year follow-up of subthalamic deep brain stimulation in Parkinson's disease. *Mov Disord* 18: 1332-1337.

Hilker R, Voges J, Ghaemi M, Lehrke R, Rudolf J, Koulousakis A, Herholz K, Wienhard K, Sturm V, Heiss WD (2003) Deep brain stimulation of the subthalamic nucleus does not increase the striatal dopamine concentration in parkinsonian humans. *Mov Disord* 18: 41-48.

Houeto JL, Mesnage V, Mallet L, Pillon B, Gargiulo M, du Moncel ST, Bonnet AM, Pidoux B, Dormont D, Cornu P, Agid Y (2002) Behavioural disorders, Parkinson's disease and subthalamic stimulation. *J Neurol Neurosurg Psychiatry* 72: 701-707.

Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. *Neurology* 57: 1497-1499.

Ichimura T, Isobe T, Okuyama T, Yamauchi T, Fujisawa H (1987) Brain 14-3-3 protein is an activator protein that activates tryptophan 5-monooxygenase and tyrosine 3-monooxygenase in the presence of Ca²⁺,calmodulin-dependent protein kinase II. *FEBS Lett* 219: 79-82.

Imperato A, Di Chiara G (1984) Trans-striatal dialysis coupled to reverse phase high performance liquid chromatography with electrochemical detection: a new method for the study of the in vivo release of endogenous dopamine and metabolites. *J Neurosci* 4: 966-977.

Itagaki C, Isobe T, Taoka M, Natsume T, Nomura N, Horigome T, Omata S, Ichinose H, Nagatsu T, Greene LA, Ichimura T (1999) Stimulus-coupled interaction of tyrosine hydroxylase with 14-3-3 proteins. *Biochemistry* 38: 15673-15680.

Justice JB, Jr., Nicolaysen LC, Michael AC (1988) Modeling the dopaminergic nerve terminal. *J Neurosci Methods* 22: 239-252.

Kaakkola S, Mannisto PT, Nissinen E (1987) Striatal membrane-bound and soluble catechol-O-methyl-transferase after selective neuronal lesions in the rat. *J Neural Transm* 69: 221-228.

Kaneda N, Kobayashi K, Ichinose H, Kishi F, Nakazawa A, Kurosawa Y, Fujita K, Nagatsu T (1987) Isolation of a novel cDNA clone for human tyrosine hydroxylase: alternative RNA splicing produces four kinds of mRNA from a single gene. *Biochem Biophys Res Commun* 146: 971-975.

Kannari K, Tanaka H, Maeda T, Tomiyama M, Suda T, Matsumaga M (2000) Reserpine pretreatment prevents increases in extracellular striatal dopamine following L-DOPA administration in rats with nigrostriatal denervation. *J Neurochem* 74: 263-269.

Kato T, Dong B, Ishii K, Kinemuchi H (1986) Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. *J Neurochem* 46: 1277-1282.

Katz B, Miledi R (1967) Ionic requirements of synaptic transmitter release. *Nature* 215: 651.

Katz B, Miledi R (1970) Further study of the role of calcium in synaptic transmission. *J Physiol* 207: 789-801.

Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. *Nature* 277: 93-96.

Kopin IJ (1987) MPTP: an industrial chemical and contaminant of illicit narcotics stimulates a new era in research on Parkinson's disease. *Environ Health Perspect* 75: 45-51.

Krack P, Batir A, Van Blercom N, Chabardes S, Fraix V, Arduoin C, Koudsie A, Limousin PD, Benazzouz A, Lebas JF, Benabid AL, Pollak P (2003) Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 349: 1925-1934.

Krack P, Benazzouz A, Pollak P, Limousin P, Piallat B, Hoffmann D, Xie J, Benabid AL (1998a) Treatment of tremor in Parkinson's disease by subthalamic nucleus stimulation. *Mov Disord* 13: 907-914.

Krack P, Limousin P, Benabid AL, Pollak P (1997) Chronic stimulation of subthalamic nucleus improves levodopa-induced dyskinesias in Parkinson's disease. *Lancet* 350: 1676.

Krack P, Pollak P, Limousin P, Hoffmann D, Xie J, Benazzouz A, Benabid AL (1998b) Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease. *Brain* 121 (Pt 3): 451-457.

Krnjevic K, Lamour Y, MacDonald JF, Nistri A (1978) Intracellular actions of monoamine transmitters. *Can J Physiol Pharmacol* 56: 896-900.

Kumar R, Lozano AM, Montgomery E, Lang AE (1998) Pallidotomy and deep brain stimulation of the pallidum and subthalamic nucleus in advanced Parkinson's disease. *Mov Disord* 13 Suppl 1: 73-82.

Lang AE, Lozano AM (1998) Parkinson's disease. First of two parts. *N Engl J Med* 339: 1044-1053.

Lee KH, Blaha CD, Harris BT, Cooper S, Hitti FL, Leiter JC, Roberts DW, Kim U (2006) Dopamine efflux in the rat striatum evoked by electrical stimulation of the subthalamic nucleus: potential mechanism of action in Parkinson's disease. *Eur J Neurosci* 23: 1005-1014.

Lee MR (1982) Dopamine and the kidney. *Clin Sci (Lond)* 62: 439-448.

Levitt M, Spector S, Sjoerdsma A, Udenfried S (1965) Elucidation of the rate-limiting step in norepinephrine biosynthesis in the perfused guinea-pig heart. *J Pharmacol Exp Ther* 148: 1-8.

Lilienfeld DE, Perl DP (1993) Projected neurodegenerative disease mortality in the United States, 1990-2040. *Neuroepidemiology* 12: 219-228.

Limousin P, Krack P, Pollak P, Benazzouz A, Ardouin C, Hoffmann D, Benabid AL (1998) Electrical stimulation of the subthalamic nucleus in advanced Parkinson's disease. *N Engl J Med* 339: 1105-1111.

Limousin P, Pollak P, Benazzouz A, Hoffmann D, Le Bas JF, Broussolle E, Perret JE, Benabid AL (1995) Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. *Lancet* 345: 91-95.

Lindberg RL, Syvalahti EK (1986) Metabolism of nomifensine after oral and intravenous administration. *Clin Pharmacol Ther* 39: 378-383.

Lopiano L, Rizzone M, Bergamasco B, Tavella A, Torre E, Perozzo P, Valentini MC, Lanotte M (2001) Deep brain stimulation of the subthalamic nucleus: clinical effectiveness and safety. *Neurology* 56: 552-554.

Marsden CD, Parkes JD (1976) "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. *Lancet* 1: 292-296.

Marsden CD, Parkes JD (1977) Success and problems of long-term levodopa therapy in Parkinson's disease. *Lancet* 1: 345-349.

Maurice N, Thierry AM, Glowinski J, Deniau JM (2003) Spontaneous and evoked activity of substantia nigra pars reticulata neurons during high-frequency stimulation of the subthalamic nucleus. *J Neurosci* 23: 9929-9936.

McIntyre CC, Grill WM (1999) Excitation of central nervous system neurons by nonuniform electric fields. *Biophys J* 76: 878-888.

McIntyre CC, Grill WM (2002) Extracellular stimulation of central neurons: influence of stimulus waveform and frequency on neuronal output. *J Neurophysiol* 88: 1592-1604.

McIntyre CC, Savasta M, Walter BL, Vitek JL (2004) How does deep brain stimulation work? Present understanding and future questions. *J Clin Neurophysiol* 21: 40-50.

Meiergerd SM, Schenk JO (1994) Striatal transporter for dopamine: catechol structure-activity studies and susceptibility to chemical modification. *J Neurochem* 62: 998-1008.

Meissner W, Guigoni C, Cirilli L, Garret M, Bioulac BH, Gross CE, Bezard E, Benazzouz A (2007) Impact of chronic subthalamic high-frequency stimulation on metabolic basal ganglia activity: a 2-deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease. *Eur J Neurosci* 25: 1492-1500.

Meissner W, Harnack D, Paul G, Reum T, Sohr R, Morgenstern R, Kupsch A (2002) Deep brain stimulation of subthalamic neurons increases striatal dopamine metabolism and induces contralateral circling in freely moving 6-hydroxydopamine-lesioned rats. *Neurosci Lett* 328: 105-108.

Meissner W, Leblois A, Hansel D, Bioulac B, Gross CE, Benazzouz A, Boraud T (2005a) Subthalamic high frequency stimulation resets subthalamic firing and reduces abnormal oscillations. *Brain* 128: 2372-2382.

Meissner W, Paul G, Reum T, Reese R, Sohr R, Morgenstern R, Kupsch A (2000) The influence of pallidal deep brain stimulation on striatal dopaminergic metabolism in the rat. *Neurosci Lett* 296: 149-152.

Meissner W, Reum T, Paul G, Harnack D, Sohr R, Morgenstern R, Kupsch A (2001) Striatal dopaminergic metabolism is increased by deep brain stimulation of the subthalamic nucleus in 6-hydroxydopamine lesioned rats. *Neurosci Lett* 303: 165-168.

Meissner W, Schreiter D, Volkmann J, Trottenberg T, Schneider GH, Sturm V, Deuschl G, Kupsch A (2005b) Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. *J Neurol* 252: 218-223.

Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. *Physiol Rev* 78: 189-225.

Molinuevo JL, Valdeoriola F, Tolosa E, Rumia J, Valls-Sole J, Roldan H, Ferrer E (2000) Levodopa withdrawal after bilateral subthalamic nucleus stimulation in advanced Parkinson disease. *Arch Neurol* 57: 983-988.

Moro E, Esselink RJ, Xie J, Hommel M, Benabid AL, Pollak P (2002) The impact on Parkinson's disease of electrical parameter settings in STN stimulation. *Neurology* 59: 706-713.

Moro E, Scerrati M, Romito LM, Roselli R, Tonali P, Albanese A (1999) Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease. *Neurology* 53: 85-90.

Nagatsu T, Levitt M, Udenfriend S (1964) Tyrosine Hydroxylase. The Initial Step In Norepinephrine Biosynthesis. *J Biol Chem* 239: 2910-2917.

Nagatsu T, Oka K, Kato T (1979) Highly sensitive assay for tyrosine hydroxylase activity by high-performance liquid chromatography. *J Chromatogr* 163: 247-252.

Nagatsu T, Yamamoto T, Nagatsu I (1970) Partial separation and properties of tyrosine hydroxylase from the human pheochromocytoma: effect of norepinephrine. *Biochim Biophys Acta* 198: 210-218.

Nakahara D, Fuchikami K, Ozaki N, Iwasaki T, Nagatsu T (1992) Differential effect of self-stimulation on dopamine release and metabolism in the rat medial frontal cortex, nucleus accumbens and striatum studied by in vivo microdialysis. *Brain Res* 574: 164-170.

Nambu A, Tokuno H, Takada M (2002) Functional significance of the cortico-subthalamo-pallidal 'hyperdirect' pathway. *Neurosci Res* 43: 111-117.

Naoi M, Takahashi T, Nagatsu T (1988) Simple assay procedure for tyrosine hydroxylase activity by high-performance liquid chromatography employing coulometric detection with minimal sample preparation. *J Chromatogr* 427: 229-238.

Nimura T, Yamaguchi K, Ando T, Shibuya S, Oikawa T, Nakagawa A, Shirane R, Itoh M, Tominaga T (2005) Attenuation of fluctuating striatal synaptic dopamine levels in patients with Parkinson disease in response to subthalamic nucleus stimulation: a positron emission tomography study. *J Neurosurg* 103: 968-973.

Nowak LG, Bullier J (1998) Axons, but not cell bodies, are activated by electrical stimulation in cortical gray matter. I. Evidence from chronaxie measurements. *Exp Brain Res* 118: 477-488.

Nutt JG (2007) Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa? *Mov Disord* 22: 1-9.

Nutt JG, Wooten GF (2005) Clinical practice. Diagnosis and initial management of Parkinson's disease. *N Engl J Med* 353: 1021-1027.

Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, Lanciego JL, Rodriguez-Diaz M (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. *Neurology* 62: S17-S30.

Okun MS, Vitek JL (2004) Lesion therapy for Parkinson's disease and other movement disorders: update and controversies. *Mov Disord* 19: 375-389.

Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershman O, Guttman M, Grandas F, Hallett M, HORNYKIEWICZ O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. *Mov Disord* 19: 997-1005.

Olanow CW, Obeso JA (2000) Pulsatile stimulation of dopamine receptors and levodopa-induced motor complications in Parkinson's disease: implications for the early use of COMT inhibitors. *Neurology* 55: S72-S77.

Ostergaard K, Sunde N, Dupont E (2002) Effects of bilateral stimulation of the subthalamic nucleus in patients with severe Parkinson's disease and motor fluctuations. *Mov Disord* 17: 693-700.

Oueslati A, Sgambato-Faure V, Melon C, Kachidian P, Gubellini P, Amri M, Kerkerian-Le Goff L, Salin P (2007) High-frequency stimulation of the subthalamic nucleus potentiates L-DOPA-induced neurochemical changes in the striatum in a rat model of Parkinson's disease. *J Neurosci* 27: 2377-2386.

Pahwa R, Wilkinson SB, Overman J, Lyons KE (2003) Bilateral subthalamic stimulation in patients with Parkinson disease: long-term follow up. *J Neurosurg* 99: 71-77.

Panova NG, Axenova LN, Medvedev AE (2000) The stimulating effects of ethanol consumption on synthesis of rat brain monoamine oxidases and their sensitivity to the irreversible inhibitor, pargyline. *Neurosci Lett* 292: 66-68.

Parkinson Study Group (2000) Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. *Parkinson Study Group. JAMA* 284: 1931-1938.

Paterson IA, Davis BA, Durden DA, Juorio AV, Yu PH, Ivy G, Milgram W, Mendonca A, Wu P, Boulton AA (1995) Inhibition of MAO-B by (-)-deprenyl alters dopamine metabolism in the macaque (*Macaca fascicularis*) brain. *Neurochem Res* 20: 1503-1510.

Paul G, Reum T, Meissner W, Marburger A, Sohr R, Morgenstern R, Kupsch A (2000) High frequency stimulation of the subthalamic nucleus influences striatal dopaminergic metabolism in the naive rat. *Neuroreport* 11: 441-444.

Paxinos W, Watson C (1997) The rat brain in stereotaxic coordinates. San Diego: Academic Press.

Payoux P, Remy P, Damier P, Miloudi M, Loubinoux I, Pidoux B, Gaura V, Rascol O, Samson Y, Agid Y (2004) Subthalamic nucleus stimulation reduces abnormal motor cortical overactivity in Parkinson disease. *Arch Neurol* 61: 1307-1313.

Pinter MM, Alesch F, Murg M, Seiwald M, Helscher RJ, Binder H (1999) Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson's disease: one year follow-up. *J Neural Transm* 106: 693-709.

Plaha P, Ben Shlomo Y, Patel NK, Gill SS (2006) Stimulation of the caudal zona incerta is superior to stimulation of the subthalamic nucleus in improving contralateral parkinsonism. *Brain* 129: 1732-1747.

Planz G, Quiring K, Palm D (1972) Rates of recovery of irreversibly inhibited monoamine oxidases: a measure of enzyme protein turnover. *Naunyn Schmiedebergs Arch Pharmacol* 273: 27-42.

Prensa L, Cossette M, Parent A (2000) Dopaminergic innervation of human basal ganglia. *J Chem Neuroanat* 20: 207-213.

Raiteri M, Cerrito F, Cervoni AM, Levi G (1979) Dopamine can be released by two mechanisms differentially affected by the dopamine transport inhibitor nomifensine. *J Pharmacol Exp Ther* 208: 195-202.

Ranck JB, Jr. (1975) Which elements are excited in electrical stimulation of mammalian central nervous system: a review. *Brain Res* 98: 417-440.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. *N Engl J Med* 342: 1484-1491.

Rascol O, Payoux P, Ory F, Ferreira JJ, Brefel-Courbon C, Montastruc JL (2003) Limitations of current Parkinson's disease therapy. *Ann Neurol* 53 Suppl 3: S3-12.

Ricardo JA (1980) Efferent connections of the subthalamic region in the rat. I. The subthalamic nucleus of Luys. *Brain Res* 202: 257-271.

Romito LM, Scerrati M, Contarino MF, Bentivoglio AR, Tonali P, Albanese A (2002) Long-term follow up of subthalamic nucleus stimulation in Parkinson's disease. *Neurology* 58: 1546-1550.

Roth RH, Murrin LC, Walters JR (1976) Central dopaminergic neurons: effects of alterations in impulse flow on the accumulation of dihydroxyphenylacetic acid. *Eur J Pharmacol* 36: 163-171.

Russmann H, Ghika J, Combremont P, Villemure JG, Bogousslavsky J, Burkhard PR, Vingerhoets FJ (2004) L-dopa-induced dyskinesia improvement after STN-DBS depends upon medication reduction. *Neurology* 63: 153-155.

Sabol KE, Richards JB, Freed CR (1990) In vivo dialysis measurements of dopamine and DOPAC in rats trained to turn on a circular treadmill. *Pharmacol Biochem Behav* 36: 21-28.

Saint-Cyr JA, Hoque T, Pereira LC, Dostrovsky JO, Hutchison WD, Mikulis DJ, Abosch A, Sime E, Lang AE, Lozano AM (2002) Localization of clinically effective stimulating electrodes in the human subthalamic nucleus on magnetic resonance imaging. *J Neurosurg* 97: 1152-1166.

Salin P, Manrique C, Forni C, Goff LK (2002) High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the Basal Ganglia in the rat. *J Neurosci* 22: 5137-5148.

Sambrook J, Russel D (2001) Molecular Cloning - A Laboratory Manual. Cold Spring Harbor, New York: Laboratory Press.

Schrag A, Quinn N (2000) Dyskinésias and motor fluctuations in Parkinson's disease. A community-based study. *Brain* 123 (Pt 11): 2297-2305.

Segal DS, Kuczynski R (1974) Tyrosine hydroxylase activity: regional and subcellular distribution in the brain. *Brain Res* 68: 261-266.

Sharp T, Zetterström T, Ungerstedt U (1986) An in vivo study of dopamine release and metabolism in rat brain regions using intracerebral dialysis. *J Neurochem* 47: 113-122.

Shen KZ, Zhu ZT, Munhall A, Johnson SW (2003) Synaptic plasticity in rat subthalamic nucleus induced by high-frequency stimulation. *Synapse* 50: 314-319.

Spiegel E, Wycis H, Marks M, Lee A (1946) Stereotaxic apparatus for operations on the human brain. *Science* 349-359.

Stefani A, Fedele E, Galati S, Pepicelli O, Frasca S, Pierantozzi M, Peppe A, Brusa L, Orlacchio A, Hainsworth AH, Gattoni G, Stanzione P, Bernardi G, Raiteri M, Mazzone P (2005) Subthalamic stimulation activates internal pallidus: evidence from cGMP microdialysis in PD patients. *Ann Neurol* 57: 448-452.

Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. *Lancet* 1: 403-406.

Srafella AP, Sadikot AF, Dagher A (2003) Subthalamic deep brain stimulation does not induce striatal dopamine release in Parkinson's disease. *Neuroreport* 14: 1287-1289.

Suneja SK, Potashner SJ (1998) Quantification of a neurotrophin receptor from submilligram quantities of brain tissue using western blotting. *Brain Res Brain Res Protoc* 3: 88-93.

Svennilson E, Torvik A, Lowe R, Leksell L (1960) Treatment of parkinsonism by stereotactic thermolesions in the pallidal region. A clinical evaluation of 81 cases. *Acta Psychiatr Scand* 35: 358-377.

Sweet RD, McDowell FH (1975) Five years' treatment of Parkinson's disease with levodopa. Therapeutic results and survival of 100 patients. *Ann Intern Med* 83: 456-463.

Tai CH, Boraud T, Bezard E, Bioulac B, Gross C, Benazzouz A (2003) Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridle neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. *FASEB J* 17: 1820-1830.

Tavella A, Bergamasco B, Bosticco E, Lanotte M, Perozzo P, Rizzone M, Torre E, Lopiano L (2002) Deep brain stimulation of the subthalamic nucleus in Parkinson's disease: long-term follow-up. *Neurol Sci* 23 Suppl 2: S111-S112.

Thobois S, Mertens P, Guenot M, Hermier M, Mollion H, Bouvard M, Chazot G, Broussolle E, Sindou M (2002) Subthalamic nucleus stimulation in Parkinson's disease: clinical evaluation of 18 patients. *J Neurol* 249: 529-534.

Tokuyama W, Hashimoto T, Li YX, Okuno H, Miyashita Y (1999) Quantification of neurotrophin-3 mRNA in the rat hippocampal subregions using the RT-PCR-based coamplification method. *Brain Res Brain Res Protoc* 4: 407-414.

Udenfriend S, Zaltzman-Nirenberg P, Nagatsu T (1965) Inhibitors of purified beef adrenal tyrosine hydroxylase. *Biochem Pharmacol* 14: 837-845.

Urbano FJ, Leznik E, Llinas RR (2002) Cortical activation patterns evoked by afferent axons stimuli at different frequencies: an in vitro voltage-sensitive dye imaging study. *Thalamus Rel Syst* 1: 371-378.

Valdeoriola F, Pillari M, Tolosa E, Molinuevo JL, Rumia J, Ferrer E (2002) Bilateral subthalamic stimulation monotherapy in advanced Parkinson's disease: long-term follow-up of patients. *Mov Disord* 17: 125-132.

Venton BJ, Zhang H, Garris PA, Phillips PE, Sulzer D, Wightman RM (2003) Real-time decoding of dopamine concentration changes in the caudate-putamen during tonic and phasic firing. *J Neurochem* 87: 1284-1295.

Vesper J, Klostermann F, Stockhammer F, Funk T, Brock M (2002) Results of chronic subthalamic nucleus stimulation for Parkinson's disease: a 1-year follow-up study. *Surg Neurol* 57: 306-311.

Vila M, Perier C, Feger J, Yelnik J, Faucheux B, Ruberg M, Raisman-Vozari R, Agid Y, Hirsch EC (2000) Evolution of changes in neuronal activity in the subthalamic nucleus of rats with unilateral lesion of the substantia nigra assessed by metabolic and electrophysiological measurements. *Eur J Neurosci* 12: 337-344.

Vingerhoets FJ, Villemure JG, Temperli P, Pollo C, Pralong E, Ghika J (2002) Subthalamic DBS replaces levodopa in Parkinson's disease: two-year follow-up. *Neurology* 58: 396-401.

Voges J, Volkmann J, Allert N, Lehrke R, Koulousakis A, Freund HJ, Sturm V (2002) Bilateral high-frequency stimulation in the subthalamic nucleus for the treatment of Parkinson disease: correlation of therapeutic effect with anatomical electrode position. *J Neurosurg* 96: 269-279.

- Volkmann J (2004) Deep brain stimulation for the treatment of Parkinson's disease. *J Clin Neurophysiol* 21: 6-17.
- Volkmann J, Allert N, Voges J, Weiss PH, Freund HJ, Sturm V (2001) Safety and efficacy of pallidal or subthalamic nucleus stimulation in advanced PD. *Neurology* 56: 548-551.
- von Campenhausen S, Bornschein B, Wick R, Botzel K, Sampaio C, Poewe W, Oertel W, Siebert U, Berger K, Dodel R (2005) Prevalence and incidence of Parkinson's disease in Europe. *Eur Neuropsychopharmacol* 15: 473-490.
- Waldmeier PC, Maitre L (1976) Comparison of short and long-lasting effects of pargyline on cerebral dopamine metabolism. *Naunyn Schmiedebergs Arch Pharmacol* 294: 133-140.
- Welter ML, Houeto JL, Bonnet AM, Bejjani PB, Mesnage V, Dormont D, Navarro S, Cornu P, Agid Y, Pidoux B (2004) Effects of high-frequency stimulation on subthalamic neuronal activity in parkinsonian patients. *Arch Neurol* 61: 89-96.
- Welter ML, Houeto JL, Tezenas du MS, Mesnage V, Bonnet AM, Pillon B, Arnulf I, Pidoux B, Dormont D, Cornu P, Agid Y (2002) Clinical predictive factors of subthalamic stimulation in Parkinson's disease. *Brain* 125: 575-583.
- Windels F, Bruet N, Poupart A, Urbain N, Chouvet G, Feuerstein C, Savasta M (2000) Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. *Eur J Neurosci* 12: 4141-4146.
- Wong PT, Teo WL, Lee T (1993) A microdialysis study on striatal dopamine, 5-HT and metabolites in conscious rats after various treatments: evidence for extravesicular release of dopamine. *Neuroreport* 5: 53-56.
- Zetterström T, Sharp T, Collin AK, Ungerstedt U (1988) In vivo measurement of extracellular dopamine and DOPAC in rat striatum after various dopamine-releasing drugs; implications for the origin of extracellular DOPAC. *Eur J Pharmacol* 148: 327-334.
- Zetterström T, Sharp T, Marsden CA, Ungerstedt U (1983) In vivo measurement of dopamine and its metabolites by intracerebral dialysis: changes after d-amphetamine. *J Neurochem* 41: 1769-1773.